Core Insights - Advancements in artificial intelligence (AI) are significantly enhancing patient care, reducing healthcare costs, and improving outcomes in the medical technology industry [1] - Generative AI is transitioning from a conceptual promise to practical applications in medical technology [1] Industry Developments - AI is expediting all phases of research and development, including generative design, virtual testing, clinical trials, and regulatory documentation [2] - The FDA is promoting the development of innovative medical devices that incorporate AI [2] Company Performance: Tempus AI (TEM) - Tempus has seen a stock increase of 27.2% over the past year, while Doximity's stock has declined by 32.8% [6] - The company is developing advanced AI algorithms and diagnostic software, collaborating with Northwestern University's Abrams Center for Alzheimer's research [7] - Tempus has received two FDA 510(k) clearances for its cardiac imaging platform and ECG-Low EF software [8] - In Q3 2025, Tempus achieved positive adjusted EBITDA of $1.5 million, with gross profit rising to $209.9 million, a 98.4% year-over-year increase [11] - EPS for 2025 is projected to be a loss of 64 cents, reflecting a 59.5% improvement from 2024 [15] Company Performance: Doximity (DOCS) - Doximity is well-positioned for AI adoption, embedding AI across its workflows and benefiting from a recent acquisition of Pathway Medical Inc. [9][13] - The company reported a 55% adjusted EBITDA margin and a 39% net income margin in fiscal 2025, with $267 million in free cash flow [14] - EPS for fiscal 2026 is projected to be $1.56, indicating a 9.9% improvement from fiscal 2025 [16] Valuation Comparison - Tempus has a forward 12-month price-to-sales (P/S) ratio of 7.24, while Doximity's is 10.38, indicating Doximity is trading at a premium [17] Conclusion - Doximity appears better positioned than Tempus, with deep AI integration, strategic acquisitions, and strong profitability metrics [18] - Tempus is recognized for its expanding AI capabilities and recent profitability milestone, indicating long-term potential in precision medicine [19]

Company Performance - Doximity (DOCS) closed at $38.96, down 3.56% from the previous trading session, underperforming the S&P 500's gain of 0.41% [1] - The company's shares have decreased by 8.66% over the past month, while the Medical sector lost 0.74% and the S&P 500 gained 0.38% during the same period [1] Upcoming Earnings - Doximity is set to release its earnings report on February 5, 2026, with an expected EPS of $0.44, reflecting a 2.22% decline compared to the same quarter last year [2] - Revenue is anticipated to be $181.03 million, which is a 7.37% increase from the prior-year quarter [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at $1.56 per share, with revenue expected to reach $645.29 million, indicating increases of 9.86% and 13.13% respectively from the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Doximity are crucial as they indicate shifts in near-term business trends, with positive revisions suggesting confidence in the company's performance [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks Doximity as 1 (Strong Buy), reflecting strong potential for outperformance [6] Valuation Metrics - Doximity has a Forward P/E ratio of 25.82, which is lower than the industry average of 27.99, indicating a valuation discount [7] - The company also has a PEG ratio of 1.36, compared to the industry average PEG ratio of 2.33, suggesting favorable growth prospects relative to its valuation [7] Industry Context - The Medical Info Systems industry, which includes Doximity, holds a Zacks Industry Rank of 82, placing it in the top 34% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1, highlighting the strength of the Medical Info Systems sector [8]

Doximity (DOCS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Ind ...

Key Points Medicare will no longer cover telemedicine services for many patients. This change will affect Teladoc Health, which was already struggling. Doximity might be less affected, but its prospects look dim as well. 10 stocks we like better than Teladoc Health › Telehealth services are convenient. There is nothing quite like being able to get some medical care, albeit virtual, from the comfort of one's home. Telehealth likely saves physicians and patients time and money. However, none of t ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. U.S. equity markets experienced a quarter shaped by optimism around potential monetary easing and caution related to economic growth and valuations. Early gains were driven by strong AI-related earnings and the US Federal Reserve’s rate cut in October. However, market sentiment cooled later in the quarter due to mixed signals from the Fed regardi ...

Voya Investment Management’s Voya MidCap Opportunities Fund released its Q4 2025 investor letter, titled “Seeking a More Favorable Risk/Return Trade-off”, outlining a quarter marked by solid market gains but relative fund underperformance. A copy of the letter can be downloaded here. During the quarter, the Fund underperformed its benchmark, the Russell Mid Cap Growth Index, primarily due to unfavorable stock selection, even as U.S. equity markets advanced on moderating inflation, robust earnings, and conti ...

Industry Overview - The Medical Info Systems industry is rapidly expanding due to innovations in healthcare resource management, patient data handling, and integrated digital care delivery [1] - Companies in this industry develop and market healthcare information systems, providing software and hardware solutions for secure access to real-time clinical, administrative, and financial data [4] Market Growth and Trends - The use of artificial intelligence (AI) in healthcare is projected to grow at a CAGR of 38.6% from 2025 to 2030, driven by demand for enhanced diagnostic accuracy and personalized medicine [2] - The global Smart Healthcare Products market was valued at $280.48 billion in 2024 and is expected to reach $796.36 billion by 2032, growing at a CAGR of 15.37% [5] - Remote patient monitoring and telehealth services are experiencing significant growth due to increased awareness of continuous patient monitoring devices [5] Key Players - Doximity (DOCS) is a market leader in physician engagement, covering over 80% of U.S. doctors, with a subscription-based revenue model and a total addressable market of $18.55 billion [17] - 10x Genomics (TXG) develops products for analyzing biological systems, with a Zacks Consensus Estimate indicating a 72.4% improvement in earnings from 2024 to 2025 [21][22] - Omnicell (OMCL) focuses on medication management solutions and is expected to achieve a revenue CAGR of 2.8% from 2025 to 2027 [25] Financial Performance - The Medical Info Systems industry has underperformed the S&P 500 and the Zacks Medical sector, losing 7.7% over the past year compared to the sector's growth of 24.7% [11] - The industry is currently trading at a forward price-to-sales (P/S) ratio of 4.65X, lower than the S&P 500's 5.65X and the sector's 2.35X [14] Cybersecurity Concerns - As healthcare systems become more digital, cybersecurity has emerged as a critical concern, with rising instances of ransomware and cyberattacks targeting healthcare organizations [7][8]

Upgrades Summary - Melius Research upgraded Wingstop (WING) to Buy from Hold with a price target of $350, increased from $275, citing an attractive entry point after recent stock weakness [2] - Seaport Research upgraded Intel (INTC) to Buy from Neutral with a price target of $65, indicating that new Panther Lakes products are expected to drive near-term improvements and market share recovery in enterprise and consumer products [2] - HSBC also upgraded Intel to Hold from Reduce with a price target of $50, up from $26 [2] - Wolfe Research upgraded Allegiant Travel (ALGT) to Outperform from Peer Perform with a price target of $108, following its acquisition of Sun Country Airlines (SNCY), described as "transformational" [2] - Wells Fargo upgraded Doximity (DOCS) to Overweight from Equal Weight with a price target of $55, down from $65, suggesting that investor concerns are overblown based on survey results indicating sufficient differentiation [2] - Morgan Stanley upgraded Brinker (EAT) to Overweight from Equal Weight with a price target of $200, increased from $160, highlighting attractive long-term growth in fast casual and beverage sectors [2] - Morgan Stanley also upgraded Shake Shack (SHAK) to Overweight from Equal Weight with a price target of $125, up from $115 [2]

Doximity, Inc. (NYSE:DOCS) is among the most promising growth stocks according to analysts. On January 9, Raymond James reaffirmed a ‘Strong Buy’ rating on Doximity, Inc. (NYSE:DOCS) and a $65 price target. The firm highlighted OpenAI’s recent entry into healthcare AI tools, which it believes is creating a “knee-jerk reaction” among investors who appeared doubtful about AI competition throughout the past year. This follows the company’s earlier stance on December 29, 2025, where Raymond James maintained a ...

Company Performance - Doximity (DOCS) closed at $41.36, down 5.7% from the previous trading session, underperforming the S&P 500's loss of 0.19% [1] - Over the past month, Doximity shares have decreased by 1.77%, while the Medical sector gained 0.48% and the S&P 500 increased by 2.26% [1] Upcoming Earnings - Doximity is expected to report an EPS of $0.44, a decrease of 2.22% compared to the same quarter last year [2] - Revenue is projected at $181.03 million, reflecting a 7.37% increase from the equivalent quarter last year [2] Annual Forecast - Zacks Consensus Estimates forecast earnings of $1.56 per share and revenue of $645.29 million for the year, indicating increases of 9.86% and 13.13% respectively compared to the previous year [3] - Changes in analyst estimates for Doximity are important as they reflect short-term business trends [3] Analyst Ratings - The Zacks Rank system rates Doximity as 2 (Buy), with a history of outperforming the market, particularly 1 stocks returning an average annual gain of 25% since 1988 [5] - The Zacks Consensus EPS estimate has increased by 0.78% in the past month [5] Valuation Metrics - Doximity has a Forward P/E ratio of 28.04, which is a discount compared to the industry average Forward P/E of 29.42 [6] - The PEG ratio for Doximity is currently 1.48, while the Medical Info Systems industry has an average PEG ratio of 2.33 [6] Industry Context - The Medical Info Systems industry is ranked 160 in the Zacks Industry Rank, placing it in the bottom 35% of over 250 industries [7] - Top-rated industries (top 50%) tend to outperform the bottom half by a factor of 2 to 1 [7]